Abstract The orexins are hypothalamic neuropeptides involved in an array of functions such as regulation of sleep/ wake states and chemoreception to CO 2 /pH. The locus coeruleus (LC) is a chemosensitive site and expresses an extensive population of orexin receptor 1 (OX1R). We tested the hypothesis that OX1Rs located in the LC participate in the ventilatory response to hypercapnia in a vigilance state and diurnal cycle-dependent manner. For this, we performed unilateral injections of SB-334867 (OX1R antagonist, 5 mM) into the LC of male Wistar rats and evaluated the ventilatory response to 7 % CO 2 during wakefulness and sleep in the dark and light phases of the diurnal cycle. Hypercapnia induced an increase in ventilation (V E ) in all groups compared to normocapnic values. However, during the dark phase, but not in the light phase, SB-334867 injection promoted an attenuation of the hypercapnic chemoreflex during wakefulness (V E : vehicle, 1502.6 ± 100 mL kg −1 min −1 vs SB-334867, 1200.3 ± 70.0 mL kg
Introduction
Central chemoreception refers to the detection of CO 2 /pH at multiple brain loci. The resultant effects on ventilation [37] and the contribution of each site varies in a statedependent manner, so that vigilance and circadian period d i ffe r e n t i a l l y m od i f y t he r e s p o n s e s o f d i s t i n c t chemosensory loci [45] . One of the brain regions that is considered an important chemoreception site is the lateral hypothalamus/perifornical area [38] , where the orexinergic neurons are located. These neurons produce a single polypeptide that is processed into two peptides orexin-A (Hcrt-1) and orexin-B (Hcrt-2) [12, 26] . Orexinergic neurons project throughout the whole central nervous system [43, 48, 53, 68] and bind to two distinct G protein-coupled receptors, orexin receptor type 1 (OX1R) and orexin receptor type 2 (OX2R). These widely distributed projections explain the various functions that are modulated by orexin, such as nociception, feeding behavior, control of energy homeostasis, sleep/wake states, stress response, and cardiovascular and respiratory control [9, 29, 34, 63, 69] .
It has been suggested that orexinergic neurons play a key role in the vigilance state-dependent control of hypercapnic chemoreflex [17, 18, 27, 66] . One of the mechanisms by which orexin modulates the hypercapnic chemoreflex is related to its projections to other chemosensitive sites such as the retrotrapezoid nucleus (RTN) and medullary raphe. For instance, in the RTN, unilateral microdialysis of OX1R antagonist in rats during the light/inactive phase of the circadian cycle resulted in a 30 % reduction of the ventilatory response to breathing, 7 % CO 2 during wakefulness, and 9 % during non-rapid eye movement (NREM) sleep [17] . In the medullary raphe, during wakefulness in the dark period, but not in the light period, OX1R antagonism caused a 16 % reduction of the ventilatory response to hypercapnia compared with the vehicle [18] . These results indicate that orexin neurons interact with chemosensitive neurons of other regions, perhaps augmenting their responses during wakefulness. Orexin levels in the brain vary according to the sleep-awake cycle; the highest levels in rodents occur during the dark-active phase and the lowest levels during the light-inactive phase [16] . Orexin levels increase just before awakening, remain high during wakefulness, and decrease during NREM sleep [58] . These arousal-promoting effects of orexin depend on its dense projections to the locus coeruleus (LC) [10, 14, 20, 22, 33, 40, 67] , which is an important CO 2 /pH chemosensitive site [6, 11, 25] . Orexin promotes depolarization in LC noradrenergic neurons in vitro and in vivo [33, 58, 65] . In addition, in situ hybridization and immunohistochemical studies demonstrate a high index of the mRNA of the orexin receptor 1 in the LC [28, 31, 64] with evidence of limited orexin receptor 2 expression [40] .
Nevertheless, despite the anatomical and functional relationship between the orexinergic neurons and LC, the role of orexinergic inputs to LC in the modulation of hypercapnic chemoreflex remains to be elucidated. Based on these facts, we hypothesized that OX1R in the LC contribute to CO 2 /pH chemoreception in a vigilance state and diurnal cycledependent manner.
Material and methods

Animals
The experiments were performed on unanesthetized adult male Wistar rats weighing 300-350 g. The animals had free access to water and food and were housed in a temperaturecontrolled chamber maintained at 24-26°C (ALE 9902001; Alesco Ltda., Monte Mor, SP, Brazil) with a 12:12-h light/ dark cycle, lights on at noon for the dark period group and at 07.00 a.m. for the light period group. The experiments were performed between 09.00 a.m. and 12.00 p.m. in the animals of the dark period group and between 01.00 p.m. and 04.00 p.m. in the animals of the light period group. The study was conducted in compliance with the guidelines of the National Council for the Control of Animal Experimentation (CONCEA, MCT, Brazil) and with the approval of the Faculty of Agricultural and Veterinary Sciences and Animal Care and Use Committee (CEUA, FACV-UNESP, Jaboticabal campus; Protocol no. 010377/14).
Drug and gas mixture
The OX1R antagonist SB-334867 (Sigma, St. Louis, MO, USA) was first dissolved in 4 % DMSO and then the solution was diluted using 35 % (2-hydroxypropyl)-β-cyclodextrin in artificial cerebrospinal fluid (aCSF) to prepare 5 mM SB-334867. For the vehicle, a solution of 4 % DMSO and 35 % (2-hydroxypropyl)-β-cyclodextrin in aCSF was used. The dose (5 mM) and method to dissolve the drug were selected as per pilot experiments and previous studies [15, 17, 18] . The gas mixtures used in this study were room air (normocapnia) and a hypercapnic gas mixture (7 % CO 2 , 21 % O 2 , balance N 2 ) purchased from White Martins Gases Industriais Ltda (Sertãozinho, SP, Brazil).
Surgical procedure and microinjection
All surgical procedures were performed under anesthesia with an intraperitoneal injection of 100 mg/kg of ketamine (Union National Pharmaceutical Chemistry S/A, Embu-Guaçu, SP, Brazil) and 10 mg/kg of xylazine (Laboratories Calier S/A Barcelona, Spain).
The head was shaved and the skin was sterilized with betadine solution and alcohol. The rats were fixed to a Kopf stereotaxic frame and implanted with a stainless steel guide cannula as previously reported [7, 23, 59, 62] . The guide cannula (0.7 mm outer diameter (o.d.) and 15-mm long) was implanted 1 mm above the LC region (distance from lambda: anterior −3.4 mm; lateral −1.2 and 1.2 mm; and dorsal −5.8 mm deep from the skull and inclination of vertical stereotaxic bar at 15°), according to the Paxinos and Watson atlas [51] . The cannula was attached to the bone using stainless steel screws and acrylic cement. A tight-fitting stylet was kept inside the guide cannula to prevent occlusion.
Three electroencephalogram (EEG) electrodes were screwed into the skull, and a pair of electromyogram (EMG) electrodes was inserted deep into the neck muscle. The skull wound was sutured. Postoperatively, the animals were treated with antibiotic (enrofloxacin, 10 mg/kg, intramuscular) and analgesic (flunixin meglumine, 2.5 mg/kg, subcutaneous) agents. The experiments were performed 7 days postoperatively.
A day before the experiments, the rats underwent a second surgery under ketamine/xylazine anesthesia for the implantation of a temperature datalogger (SubCue Dataloggers, Calgary, Canada) into the abdominal cavity through a midline laparotomy. The datalogger was programmed to acquire data every 5 min.
A 5-μL Hamilton syringe and a dental injection needle (Mizzy, 200 μm o.d.) connected to a PE-10 tube were used to perform the microinjections into the LC of unanesthetized rats. The injection needle was 1 mm longer than the guide cannula so that the LC was reached by the needle only at the time of injection. A volume of 0.1 μL of the vehicle or drug solution was injected over a period of 30 s. Following the injection, the needle was removed from the guide cannula after an additional 30 s to avoid reflux. All injections were performed using a microinjector machine (model 310, Stoelting Co., IL, USA).
Determination of pulmonary ventilation
Measurements of pulmonary ventilation (V E ) were performed using the whole body plethysmography method [4] as commonly used in our laboratory [6, 11, 50] .
Freely moving rats were kept in a 5-L chamber ventilated with room air or a hypercapnic gas mixture containing 7 % CO 2 (White Martins, Sertãozinho, Brazil) in low ambient noise conditions. The flow rate of the inflow gas into the animal chamber was monitored by a flowmeter (model 822-13-OV1-PV2-V4, Sierra Instruments, Monterey, CA). During measurements, the flow was interrupted, and the chamber was sealed for short periods of time (approximately 2 min); the pressure oscillations due to respiration were monitored by a differential pressure transducer (TSD 160A, Biopac Systems, Santa Barbara, CA). The signals were fed into a differential pressure transducer (DA 100C, Biopac Systems), passed through an analog-to-digital converter, and digitized on a microcomputer equipped with data acquisition software (MP100A-CE, Biopac Systems). The sampling frequency was 1-kHz samples per second. The results were analyzed using the data analysis software Acqknowledge (v. 4.2.3 data acquisition system, Biopac Systems). Tidal volume (V T ) and respiratory frequency (fR) were calculated per breath to estimate ventilation per breath. V T was calculated by using an appropriate formula [4] . The vapour pressure of water vapour in the animal chamber was calculated indirectly using an appropriate table [13] . The calibration for volume was obtained during each experiment by injecting the animal chamber with 1 mL of air.
EEG and EMG signals
The arousal state was determined by analyzing the EEG and EMG records as previously described [44] . The signals from the EEG and EMG electrodes were sampled at 1 kHz, filtered at 0.3-50 and 0.1-100 Hz, respectively, and recorded on the computer. Both wakefulness and NREM sleep states were observed consistently through the experiments, but periods of rapid eye movement (REM) sleep were short and were not present in every experiment; thus, REM sleep periods were excluded from the analysis.
Experimental protocol
At 7 days after the unilateral implantation of guide cannulae, the animals were individually placed in a Plexiglass chamber (5 L) and allowed to move freely while the chamber was flushed with atmospheric air. After approximately 40 min of acclimatization period, the control V E was measured before the microinjection. Subsequently, 0. 1 μ L of veh icle or SB 33 4867 (5 mM) w as microinjected into the rat LC. Respiratory measurements were performed 7, 14, 21, 28, 35, and 42 min after the microinjection under normocapnic conditions. Then, based on the sleep/wake cycle, for the V E measurements, we selected the period when the animals were in wakefulness or in sleep. The core body temperature was measured at 5 min intervals throughout the experiment. For the hypercapnia groups, after the control V E measurement, a hypercapnic gas mixture (7 % inspired CO 2 in air) was flushed through the chamber for 10 min, and then the rats received 0.1 μL of vehicle or SB 334867 into the LC, followed by subsequent measurements during the addition of 7 % CO 2 . The experiments were performed in different groups of animals during the dark and light phases of the diurnal cycle.
Histology
Upon completion of the experiments, the animals were deeply anesthetized with ketamine and xylazine and perfused intracardially with saline followed by 10 % formalin solution for 10 min (5 min for each solution). A needle injector (19.6-mm long) was inserted through the guide cannula and a 0.1-μL microinjection of Evan's blue was performed. The brain was removed and stored in 10 % formalin for at least 2 days. After fixation, the brainstem was embedded in paraffin, sectioned on a microtome (15-μm-thick coronal sections), and stained by the Nissl method for light microscopy determination of the region reached by the microinjection, according to the Paxinos and Watson atlas [51] . Only the rats with a positive site of microinjection into the LC were considered.
Data processing and analysis
The results are expressed as mean ± SEM. The normocapnic and hypercapnic conditions were analyzed separately to determine the effect of drug microinjection. The effects of SB-334867 microinjection on the ventilatory variables, body temperature, and the percentage time spent in each arousal state were evaluated by two-way analysis of variance with phase of the day and drug as factors and a Bonferroni post hoc test to assess the differences between the groups. A P value of <0.05 was considered to be statistically significant. All statistical analyses were performed using SigmaStat 274 (v3.5, Systat Software Inc., San Jose, CA, USA).
Results
Histology Figure 1 is a representative photomicrograph of the transverse section of the rat brainstem through the region of LC injection.
Effect of SB-334867 microinjection intra-LC on ventilation during room air and 7 % CO 2 during the dark period During normocapnia, the microinjection of SB-334867 intra-LC had no effect on V E , in wakefulness, or in sleep during the dark period (Fig. 2) . Hypercapnia elicited an increase in ventilation in all the groups (P < 0.0001, Fig. 2) . However, the CO 2 response in the SB-334867 group was attenuated during wakefulness (V E vehicle, 1502.6 ± 100 mL kg
SB-334867, 1200.3 ± 70.0 mL kg
, P < 0.05) but not during sleep (V E vehicle, 1383.0 ± 113.9 vs V E SB-334687, 1287.6 ± 92.1 mL kg
) (Fig. 2) . The reduction in V E was due to a decreased V T (V T vehicle, 11.3 ± 0.7 vs V T SB-334687, 8.8 ± 0.3 mL kg
−1
). The effect was specific for intra-LC injection since peri-LC injections did not have the same effect (V E peri-LC, 1760.2 ± 105.1 mL kg
; data not shown in the graph).
Effect of SB-334867 microinjection intra-LC on ventilation during room air and 7 % CO 2 during the light period Under room air conditions, SB-334867 microinjection intra-LC did not change V E , V T , and fR during wakefulness and sleep in the light period (Fig. 3) . Hypercapnia induced an increase in ventilation in all the groups (P < 0.0001), although different from the dark period; the SB-334867 treatment caused no effect on the ventilatory response to CO 2 in wakefulness or in sleep (Fig. 3) .
Effect of SB-334867 microinjection intra-LC on Tb
No difference was observed between the OX1R antagonisttreated and vehicle-treated animals in terms of Tb during normocapnic or hypercapnic conditions in the dark (Fig. 4a ) or in the light period (Fig. 4b) . Hypercapnia caused a drop in Tb in all the groups in both periods (P < 0.05).
Effect of SB-334867 microinjection intra-LC on the time spent in each arousal state, during dark and light periods Under room air condition, during the dark period (Fig. 5a) , the rats spent more time awake, compared to NREM sleep, but the OX1R antagonist treatment decreased the total period of wakefulness compared with the vehicle-treated animals (1247.5 ± 173.2 s in the SB-334867 group vs 1941.8 ± 157.5 s in the control group; P < 0.05; Table 1 ). This effect was due to a significant reduction in the length of the episodes of wakefulness, while the number of episodes did not change. CO 2 significantly increased the time the rats were awake (Fig. 5a ), but the SB-334867 treatment shortened the wakefulness episodes (P < 0.05; Table 1 ). However, this effect did not result in a significant difference in the total time spent in wakefulness.
During the light period (Fig. 5b) , under normocapnia, the OX1R blockade did not change the time the rats spent in wakefulness, but during hypercapnia, the SB-334867-treated animals were less awake than the control group (P < 0.05). This effect was due to a decreased duration of the wakefulness episodes and the number of episodes (P < 0.05; Table 2 ).
Discussion
In the present study, we suggest that orexin acting on OX1R of the LC neurons in unanesthetized adult rats contributes to the increase in ventilation in response to hypercapnia during wakefulness in the dark phase. The effect was specific in V T but not in fR. In addition, these receptors do not have a tonic role in ventilatory control, because no effect was observed under normocapnic conditions during wakefulness and during NREM sleep in the dark and light phases.
Previous studies have demonstrated that orexin stimulates breathing. Orexinergic projections and receptors are found in the brainstem regions involved in the control of breathing, including the rostral ventrolateral medulla (RVLM), Kölliker-Fuse nucleus, nucleus of the solitary tract (NTS), dorsal vagal motor nucleus, hypoglossal motor nucleus, and phrenic motor nuclei [39, 46, 67] . Orexin A injected into the RVLM or phrenic nucleus increased the amplitude of diaphragm EMG activity in anesthetized and vagotomized rats [67] , while the injection of orexin B into the pontine Kölliker-Fuse nucleus, in a perfused rat brainstem preparation, intra- Fig. 1 Representative photomicrograph of a microinjection into the locus coeruleus (LC) of rat. The figure shows a coronal section at the pons level illustrating the LC location (dashed circle) and a typical intra-LC microinjection (black arrow) increased the respiratory frequency and the preinspiratory hypoglossal nerve activity [27] . In the current study, we showed that microinjection of SB-334867 intra-LC did not change the ventilation under room air conditions. Our result is consistent with previous data showing that spontaneous breathing was not different between wild-type and prepo-orexin knockout mice [15] . Similarly, selective inhibition of both the orexin receptors using a dual orexin receptor antagonist, administered orally, did not change breathing at rest [37] , and the microdialysis of SB-334867 in the rostral medullary raphe and RTN did not affect ventilation during normocapnia, either in wakefulness or in sleep, during the dark and light phases of the diurnal cycle [17, 18] . Therefore, previous studies and the present results suggest that the orexinergic system acting on the LC, RTN, and rostral medullary raphe plays no tonic role during breathing at rest.
Hypercapnia augmented ventilation in all the groups, due to an increase in V T and fR. However, the microinjection of SB-334867 intra-LC attenuated the ventilatory response to hypercapnia by 25 %, during wakefulness in the dark but Values are shown as mean ± S.E.M. Asterisk indicates significant differences between SB-334867 and vehicle groups. Plus sign indicates significant differences between normocapnic and hypercapnic groups not in the light period. This attenuation was due to a decreased V T . Therefore, our data corroborate previous studies, which demonstrated that orexin plays an excitatory role in the hypercapnic ventilatory response during wakefulness [17, 18, 37, 38, 42, 66] .
Orexins are important in the modulation of the central chemoreflex [15, 17, 18, 27, 42, 66] . In the present study, the ventilatory response to hypercapnia was attenuated after the injection of OX1R antagonist in the LC during wakefulness in the dark phase but not during sleep or in the light phase. The lack of effect of SB-334867 on respiratory variables during the light phase is consistent with orexin's circadian oscillation: it has little effect because there is little presynaptic orexin release [16] . Figure 6 depicts proposed LC orexinergic neurotransmission mechanisms based on the present data and evidence from the literature [10, 14, 20, 22, 33, 38, 40, 58, 65, 67] . During the dark phase, orexin A release is elevated and modulates the response of chemosensory signaling pathways in LC. Then, orexin A activates noradrenergic neurons that induce noradrenaline release which project to the Antagonism of ORX1 receptors may decrease the release of noradrenaline (NOR) from LC, leading to a reduction in the CO 2 drive to breath. Similarly, Dias et al. [18] , using microdialysis of SB-334867 in the medullary raphe, observed a decrease of 16 % in the ventilatory response to CO 2 during wakefulness in the dark phase. In another study, Dias et al. [17] demonstrated that the microdialysis of the same OX1R antagonist, but in the RTN, elicited a 30 % reduction in the ventilatory response to CO 2 during wakefulness and a reduction of 9 % during NREM sleep. These observations and the present study results support the hypothesis that the one mechanism by which orexinergic neurons modulate breathing is through OX1Rs located in different chemosensitive nuclei, such as the RTN, medullary raphe, and, as we have shown here, the LC.
The fact that the participation of orexin is dependent on the vigilance state is consistent with the well-established notion that the orexinergic neurons are essential to promote and consolidate wakefulness [27, 46] . Narcolepsy results from the loss of hypothalamic orexin/hypocretin neurons [12, 56] . Orexinergic neurons present inputs to the primary nuclei involved in the control of wakefulness [47, 53, 54] . Moreover, recordings of the activity of these neurons demonstrated that their discharge is state dependent [36, 41] , because the activity of these neurons is high during wakefulness and decreases during NREM sleep [60] . Similarly, c-fos expression in orexinergic neurons is higher during wakefulness and lower during REM and NREM sleep [21] .
In the present study, we limited the room air and hypercapnia periods to ∼40 min each, which is appropriate to study the hypercapnic ventilatory responses but is not well suited to evaluate completely the characteristics of wakefulness and NREM sleep. To do so, it would be necessary many hours of EEG/EMG recordings along the experiment. However, even considering this limitation of recording time, we show that (1) the rats spent less time in sleep during hypercapnia compared with normocapnia, which was expected due to the arousal effect of CO 2 and (2) the OX1R blockade in the LC shortened the time the rats were awake during normocapnia in the dark but not in the light period. This effect was due to a reduction in the length of the awake episodes while the frequency of episodes did not change. (3) During hypercapnia, the inhibition of OX1Rs on the LC decreased the duration of awake episodes not only in the dark but also in the light period, but the total time spent in wakefulness was reduced just in the light period which is the inactive period of the rat diurnal cycle. Overall, these results are consistent with the arousalpromoting effect of orexin neurons and with their role in the maintenance of wakefulness, which could explain the fact that OX1R blockade shortened the duration of awake episodes. These results also corroborate with data from previous studies showing that the oral administration of a dual orexin receptor antagonist, almorexant, caused a 56 % decrease in the percentage time in wakefulness in rats [37] , while it induced somnolence in rats, dogs, and humans [8] .
Similar to the orexinergic neurons, the firing rate of LC noradrenergic neurons is also state dependent, being active during wakefulness, reducing their activity during non-REM sleep, and almost silent during REM sleep [2, 3, 32] . Corroborating these data, Shouse et al. [57] demonstrated that there is a progressive decline of noradrenaline release from [30, 39, 49] . Therefore, it is expected that the participation of orexin receptor 1 in the LC is specific during wakefulness, as suggested by the results of this study. Regarding body temperature, the orexinergic neurons are located in the dorsomedial hypothalamus (DMH), which is involved in the integration and coordination of multiple thermoeffectors [19] . Because LC is also involved in thermogenesis, particularly during fever [1] , we considered the possibility that LC OX1R antagonism affects body temperature.
Our data demonstrated that SB-334867 intra-LC microinjection did not change the Tb of rats under euthermic conditions. Our data corroborate previous studies from our laboratory showing that specific lesions of LC noradrenergic neurons did not change the Tb of rats under euthermia in normocapnia or hypercapnia, suggesting that noradrenergic neurons of the LC play no role in Tb regulation under these euthermic conditions [6] .
We observed that hypercapnia promoted a decrease in Tb during the light and dark phases in all the groups. CO 2 exposure causes a decrease in Tb due to heat loss during hyperpnea and vasodilatation [5, 35, 55] . Hypercapnia promotes an Fig. 6 Schematic drawing depicting a possible mechanism of orexinergic signaling in the locus coeruleus (LC). During the dark phase, orexin A release from the lateral hypothalamus (LH) is elevated and modulates the response of chemosensory signaling pathways in LC. Orexin A binds on ORX1 receptors in the LC (red arrows) and induces depolarization of noradrenergic neurons and noradrenaline (NOR) release which project to the central respiratory pattern generator (CPG) or directly to the respiratory premotoneurons, causing an increase in the activity of these neurons, promoting an increase in ventilation. Antagonism of ORX1 receptors by SB-334867 (blue arrows) may decrease the release of NOR from LC, leading to a reduction in the CO 2 drive to breath increase in the activity of neurons of the preoptic area of the anterior hypothalamus [61] . Moreover, a study in newborn mice showed that the rectal temperature decreases when the animals are exposed to 6 % CO 2 [24] . There was also a complete inhibition of thermogenesis in mice, when they were subjected to gas mixtures containing 10 % or more of CO 2 [52] . As observed during normocapnic conditions, SB-334867 intra-LC microinjection did not affect the drop in Tb during CO 2 challenge, suggesting that orexin acting in OX1R receptors in LC does not modulate the hypercapnia-induced hypothermia. However, we cannot exclude the possibility that ORX1 receptors in the LC may be involved in Tb regulation during specific types of thermal stress, such as exposure to cold or heat. Future studies are needed to clarify this issue.
V E
In conclusion, we suggest that projections of orexincontaining neurons to the LC contribute, via OX1Rs, to the hypercapnic chemoreflex during wakefulness in the dark phase, indicating that this pathway may be involved in the vigilance state and diurnal cycle-dependent control of CO 2 drive to breathing.
